Innoviva Inc (INVA)
Gross profit margin
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gross profit (ttm) | US$ in thousands | 171,290 | 156,763 | 161,887 | 206,560 | 218,050 | 285,244 | 342,616 | 341,666 | 356,609 | 337,238 | 327,863 | 307,819 | 304,580 | 300,196 | 275,459 | 258,769 | 234,721 | 238,608 | 234,931 | 242,507 |
Revenue (ttm) | US$ in thousands | 291,306 | 265,493 | 264,791 | 292,746 | 287,188 | 335,952 | 366,863 | 358,359 | 372,796 | 355,782 | 346,801 | 325,125 | 318,463 | 308,609 | 285,580 | 270,641 | 247,045 | 250,932 | 246,312 | 253,952 |
Gross profit margin | 58.80% | 59.05% | 61.14% | 70.56% | 75.93% | 84.91% | 93.39% | 95.34% | 95.66% | 94.79% | 94.54% | 94.68% | 95.64% | 97.27% | 96.46% | 95.61% | 95.01% | 95.09% | 95.38% | 95.49% |
December 31, 2023 calculation
Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $171,290K ÷ $291,306K
= 58.80%
The gross profit margin of Innoviva Inc has shown a declining trend over the past eight quarters, starting at 100% in Q2 2022 and gradually decreasing to 86.27% in Q4 2023. This indicates that the company's profitability from sales has been decreasing over time. The most significant drop occurred from Q1 to Q2 2023, where the margin fell from 92.40% to 88.60%. It is important for the company to closely monitor and analyze the factors contributing to this trend, as a decreasing gross profit margin can impact overall profitability and financial health.
Peer comparison
Dec 31, 2023
Company name
Symbol
Gross profit margin
Innoviva Inc
INVA
58.80%
Abbott Laboratories
ABT
20.40%
AbbVie Inc
ABBV
32.16%
Alkermes Plc
ALKS
29.02%
Amphastar P
AMPH
54.49%
ANI Pharmaceuticals Inc
ANIP
11.30%
Arcus Biosciences Inc
RCUS
-4.27%
Biomarin Pharmaceutical Inc
BMRN
78.98%
Bristol-Myers Squibb Company
BMY
37.48%
Catalent Inc
CTLT
21.82%
Catalyst Pharmaceuticals Inc
CPRX
49.46%